#efsitora
LightNews LightNews
embers.news
FDA Approves Eli Lilly’s Onswik for Once-Weekly Type 2 Diabetes Treatment

The U.S. Food and Drug Administration has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a…

Read more: https://embers.news/article/fda-approves-eli-lillys-onswik-for-once-weekly-type-2-diabetes-treatment-257087
FDA Approves Eli Lilly’s Onswik for Once-Weekly Type 2 Diabetes Treatment
The U.S. Food and Drug Administration has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. The approval, granted on September 24, 2026, provides a new treatment option for patients who currently manage their condition through dail
embers.news
September 29, 2026 at 2:31 PM
casstee2000.bsky.social
www.medpagetoday.com/endocrinolog...
If this really works it would be fantastic
FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
Approval marks the second once-weekly basal insulin for this population
www.medpagetoday.com
September 28, 2026 at 2:20 PM
nkov.bsky.social
www.medscape.com/viewarticle/...
FDA Approves Efsitora Once-Weekly Basal Insulin Injection
The approval adds a second long-acting, injectable option for the treatment of type 2 diabetes.
www.medscape.com
September 27, 2026 at 12:22 AM
medpagetoday.com
The FDA approved the once-weekly basal insulin efsitora (Onswik), drugmaker Eli Lilly announced on Thursday.
https://www.medpagetoday.com/endocrinology/diabetes/123153
FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
Approval marks the second once-weekly basal insulin for this population
www.medpagetoday.com
September 25, 2026 at 8:14 PM
mdspirenews.bsky.social
💉 FDA approves once-weekly insulin for adults with type 2 diabetes.

Four phase 3 trials found insulin efsitora alfa-gobe noninferior for HbA1c reduction vs once-daily basal insulin comparators.

Read more: https://ow.ly/hMoS50ZRrx9

#Diabetes #FDA
September 25, 2026 at 2:55 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApprovals https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 8:38 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApproval https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 7:38 PM
sstrumello.bsky.social
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with Type 2 diabetes @prnewswire.bsky.social www.prnewswire.com/news-release...
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
/PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a...
www.prnewswire.com
September 24, 2026 at 5:46 PM
rankednews.bsky.social
Eli Lilly: New type 2 diabetes jab could slash number of injections to one a week: The National Institute for Health and Care Excellence (Nice) has recommended a new weekly insulin treatment for type 2 diabetes, known as Onswik (insulin efsitora alfa) and manufacture… https://ranked.news/1268984?u=b
Article image
August 21, 2026 at 12:08 AM
mimsonline.bsky.social
The first once-weekly basal insulin (efsitora alfa, also known as Onswik) has been provisionally recommended by NICE for people with type II diabetes.

Read more on MIMS
buff.ly/yhyZCPB
First once-weekly insulin recommended by NICE
NICE has recommended insulin efsitora alfa for people with type II diabetes, in final draft guidance published today.
www.mims.co.uk
August 20, 2026 at 2:00 PM
rankednews.bsky.social
New type 2 diabetes jab could cut number of injections by 86 per cent: The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending insulin efsitora alfa, a weekly treatment for type 2 diabetes. This new jab, also branded … https://ranked.news/1267708?u=b
Article image
August 20, 2026 at 6:00 AM
adapubs.bsky.social
Once-weekly efsitora achieves similar HbA1c reduction to daily insulin with fewer nocturnal hypoglycemia events, suggesting improved safety and convenience for managing type 2 diabetes. #DOCM

Read here ➡️ doi.org/10.2337/doc25-0066
Flowchart illustrating the study selection process. It begins with identification, showing records from databases such as PubMed, Scopus, Cochrane, and WOS totaling 267. From the Registry, records from ClinicalTrials.gov are 1. After removing duplicates, 267 records undergo screening by title and abstract, leading to 18 full-text reports assessed for eligibility. Of these, 5 studies are included in the final review. The chart includes reasons for exclusion, such as study design and type of diabetes, with colored arrows indicating the selection path.
April 22, 2026 at 6:15 PM
nejm.org
📖 Further reading 
Original Article by J. Rosenstock et al.: Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy (QWINT-1 trial) nej.md/4jX5R59
February 15, 2026 at 5:01 PM
springermedicine.com
A round-up of the #QWINT phase 3 clinical trials evaluating once-weekly #insulin efsitora alfa in people with diabetes, including data simultaneously published and presented at the ADA's 85th Scientific Sessions.

👉 buff.ly/5IZShab

#Diabetes
December 17, 2025 at 4:15 PM
shihcheng.bsky.social
NEJM: A 52-week phase 3 trial finds once-weekly efsitora alfa effective for Type 2 diabetes. Adults show improvement without prior insulin use. PMID:40548694, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2502796 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2502796
No description available
doi.org
September 9, 2025 at 12:10 PM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 9:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 8:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 7:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 6:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 5:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 4:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 3:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 2:09 AM
tsubodaisuki.bsky.social
週1回投与のinsulin efsitoraはインスリン頻回注射療法中の2型糖尿病患者においても有効である（解説：住谷 哲 氏）－1995 - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTE82ajV0NmctbFNTYnRoZVVTS3U3UzVlS3hNMXdNZHUyOFd1UGZBSFgtdkU4Y0hHWkx3NXFBVlZhU1ViMEZicldFa2JLa0hOb2FLMThjMXlrVTZsNUJw?oc=5
August 10, 2025 at 1:09 AM
nejm.org
QWINT-1 phase 3 trial: Basal insulin is recommended for patients with type 2 diabetes that is not well controlled with noninsulin glucose-lowering agents, but daily injections can be burdensome. Research findings on weekly basal insulin are summarized in a new Quick Take video. nej.md/4f4zdhf
An illustration of trial participants with type 2 diabetes who received either once-weekly insulin efsitora alfa in a fixed-dose regimen or once-daily insulin glargine U100 with weekly sliding-scale dose adjustments
July 30, 2025 at 4:05 PM